- $115.66m
- $107.98m
- $44.86m
- 45
- 19
- 20
- 18
Annual balance sheet for Augmedix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-Q | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 9.6 | 20.8 | 41.3 | 21.3 | 46.2 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2.29 | 2.69 | 7.18 | 6.35 | 8.57 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 14.4 | 26.8 | 50.8 | 29.6 | 56.8 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.21 | 0.992 | 0.982 | 3.14 | 8.96 |
Other Long Term Assets | |||||
Total Assets | 15.7 | 27.9 | 52.1 | 33.6 | 66.7 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 12.9 | 16.5 | 14 | 19.3 | 23.6 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 27 | 24.8 | 28 | 32.2 | 43.4 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -11.3 | 3.12 | 24.1 | 1.47 | 23.3 |
Total Liabilities & Shareholders' Equity | 15.7 | 27.9 | 52.1 | 33.6 | 66.7 |
Total Common Shares Outstanding |